NCT03845010

Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment

Elimination of Ventricular Premature Beats With CaTheter Ablation Versus OPtImal Anti-arrhythmic Drug Treatment

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Maatschap Cardiologie Zwolle · Academic / Other
• Sex: All
• Age: 76 Years
• Healthy volunteers: Not accepted

Summary

The ECTOPIA trial is a randomized, multicenter, clinical trial to assess elimination of ventricular premature beats (VPB) with catheter ablation versus optimal anti-arrhythmic drugs (AAD) treatment with flecainide/verapamil or sotalol.

Detailed description

The ECTOPIA trial is a randomized, multicenter, clinical trial to assess elimination of VPB with catheter ablation versus optimal AAD treatment with flecainide/verapamil or sotalol. Due to the use of different AAD (with and without beta-blocking abilities) the investigators will be able to explore the secondary objectives. Finally, this study will assess safety of ablation of non-RVOT VPBs and long-term treatment with two different AAD.

Conditions

• Ventricular Premature Beats

Interventions

Type	Name	Description
DRUG	Sotalol	Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)
DRUG	Flecainide and verapamil	Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day
PROCEDURE	Catheter ablation	Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine

Timeline

• Start date: 2019-02-12
• Primary completion: 2023-01-17
• Completion: 2023-01-17
• First posted: 2019-02-19
• Last updated: 2023-06-28

Locations

1 site across 1 country: Netherlands